-
Ruxolitinib, sold
under the
brand name
Jakafi among others, is a
medication used for the
treatment of
intermediate or high-risk myelofibrosis, a type...
-
Administration (FDA)
approved ruxolitinib (Jakafi) as a
treatment for
intermediate or high-risk myelofibrosis.
Ruxolitinib serves as an
inhibitor of JAK...
- Food and Drug
Administration (FDA)
approved the
first JAK inhibitor,
ruxolitinib, to
treat a skin condition. Some JAK1
inhibitors are
based on a benzimidazole...
- pimecrolimus) are
considered to be first-line
vitiligo treatments. In July 2022,
ruxolitinib cream (sold
under the
brand name Opzelura) was
approved for
medical use...
-
pharmaceutical products,
including Jakafi (
ruxolitinib),
Pemazyre (pemigatinib),
Monjuvi (tafasitamab-cxix) ,
Opzelura (
Ruxolitinib),
Tabrecta (capmatinib), Olumiant...
- by Eli
Lilly and Pfizer.
Deuruxolitinib is a
deuterated derivative of
ruxolitinib. King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne;...
- disease. Many
clinical trials are
ongoing involving JAK
inhibitors such as
ruxolitinib and tofacitinib.
Alopecia areata Alopecia totalis "Alopecia universalis...
- arthritis,
psoriatic arthritis, and
ulcerative colitis; fedratinib, and
ruxolitinib. The
substance is
quickly absorbed from the gut with an
absolute bioavailability...
-
published in
tandem with a
phase II
clinical trial showing the same for
ruxolitinib. In a June 2015 case report, a 53-year-old
woman with
vitiligo showed...
- are used in the
treatment of
seborrheic dermatitis. In
September 2021,
ruxolitinib cream (Opzelura) was
approved by the U.S. Food and Drug Administration...
